CYP19 Genetic Polymorphism Haplotype AASA Is Associated with a Poor Prognosis in Premenopausal Women with Lymph Node-Negative, Hormone Receptor-Positive Breast Cancer

Table 1

Pertinent clinicopathologic features of the LN-negative, HR-positive breast cancer patients.

Characteristic	Number of patients (𝑁=296)
Age (years)
Median (range)	50 (24–81)
HER-2/neu status
0	65 (22.0)
1	62 (20.9)
2	38 (12.8)
3	41 (13.9)
Missing	90 (30.4)
Menopausal status
Premenopausal	178 (60.1)
Postmenopausal	118 (39.9)
Pathology
Infiltrating ductal ca. + infiltrating lobular; ca. + medullary ca.	253 (85.5)
Other	43 (14.5)
Grade
I	127 (42.9)
II	131 (44.3)
III	38 (12.9)
Tumor size (cm)
≤2	171 (57.8)
>2–5	125 (42.2)
Hormone receptor status
ER (+) PR (+)	220 (74.3)
ER (+) PR (−)	45 (15.2)
ER (−) PR (+)	31 (10.5)
Adjuvant hormone therapy
Tamoxifen	269 (90.9)
Others*	27 (9.1)
Adjuvant chemotherapy
No CT	162 (54.7)
CT	134 (45.3)

LN: lymph node; HR: hormone receptor; ca: cancer; ER: estrogen receptor; PR: progesterone receptor; CT: chemotherapy.
*Ovarian ablation or luteinizing hormone-releasing hormone.